A Phase 2 interventional study of Lanraplenib and Filgotinib in Sjogren's Syndrome, sponsored by Gilead Sciences. Completed at 53 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-10-23.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 24th largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2017, is one of 30 in phase 2, and was the 52nd registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
Vor Biopharma · Sites in United States, Georgia
Ages 18–75
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 1 study filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
Drug: Lanraplenib · Drug: Filgotinib placebo · Drug: Tirabrutinib placebo
Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
Drug: Filgotinib · Drug: Lanraplenib placebo · Drug: Tirabrutinib placebo
Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
Drug: Tirabrutinib · Drug: Lanraplenib placebo · Drug: Filgotinib placebo
Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48: * filgotinib + lanraplenib placebo + tirabrutinib placebo * lanraplenib + filgotinib placebo + tirabrutinib placebo * tirabrutinib + filgotinib placebo + lanraplenib placebo
Drug: Lanraplenib · Drug: Filgotinib · Drug: Tirabrutinib · Drug: Lanraplenib placebo · Drug: Filgotinib placebo · Drug: Tirabrutinib placebo
1 x 30 mg tablet administered orally once daily
Also known as: GS-9876
1 x 200 mg tablet administered orally once daily
Also known as: GS-6034
1 x 40 mg tablet administered orally once daily
Also known as: GS-4059
1 x tablet administered orally once daily
1 x tablet administered orally once daily
1 x tablet administered orally once daily
Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline
Response was defined as: Improvement ≥ 20% in ≥ 3 of 5 participant-reported Sjogren's syndrome (SjS) related visual analogue score (VAS) measures (participant's assessment of global disease, pain, oral dryness, ocular dryness and fatigue), with no increase defined as \> 30 mm from baseline (Day 1) in any of the above 5 VAS measures, AND either ≥ 20% improvement in high sensitivity C-reactive protein (hsCRP) (if hsCRP ≥ 1.5 x upper limit of normal \[ULN\] on Day 1) or no increase in hsCRP to ≥ 1.5 x ULN (if hsCRP \< 1.5 x ULN on Day 1).
Time frame: Week 12
Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12
The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.
Time frame: Baseline; Week 12
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12
The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.
Time frame: Baseline; Week 12
Change From Baseline in ESSDAI at Week 24
The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.
Time frame: Baseline; Week 24
Change From Baseline in ESSPRI at Week 24
The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.
Time frame: Baseline; Week 24
Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 01 May 2017. The last study visit occurred on 02 October 2019.
| Milestone | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Placebo to Lanraplenib | Placebo to Filgotinib | Placebo to Tirabrutinib |
|---|---|---|---|---|---|---|---|
| Started | 38 | 38 | 39 | 37 | 0 | 0 | 0 |
| Completed | 26 | 29 | 33 | 32 | 0 | 0 | 0 |
| Not completed | 12 | 9 | 6 | 5 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 4 | 5 | 3 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but didn't receive study drug | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Placebo to Lanraplenib | Placebo to Filgotinib | Placebo to Tirabrutinib |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 12 | 10 |
| Completed | 0 | 0 | 0 | 0 | 10 | 12 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Response was defined as: Improvement ≥ 20% in ≥ 3 of 5 participant-reported Sjogren's syndrome (SjS) related visual analogue score (VAS) measures (participant's assessment of global disease, pain, oral dryness, ocular dryness and fatigue), with no increase defined as \> 30 mm from baseline (Day 1) in any of the above 5 VAS measures, AND either ≥ 20% improvement in high sensitivity C-reactive protein (hsCRP) (if hsCRP ≥ 1.5 x upper limit of normal \[ULN\] on Day 1) or no increase in hsCRP to ≥ 1.5 x ULN (if hsCRP \< 1.5 x ULN on Day 1).
| percentage of participants | Lanraplenib | Filgotinib | Tirabrutinib | Placebo |
|---|---|---|---|---|
| Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline | 42.9 (25.0 to 60.7) | 43.2 (25.9 to 60.6) | 35.1 (18.4 to 51.9) | 26.5 (10.2 to 42.8) |
The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.
| score on a scale | Lanraplenib | Filgotinib | Tirabrutinib | Placebo |
|---|---|---|---|---|
| Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12 | -2.5 ± 0.76 | -4.7 ± 0.72 | -3.2 ± 0.73 | -3.9 ± 0.76 |
The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.
| score on a scale | Lanraplenib | Filgotinib | Tirabrutinib | Placebo |
|---|---|---|---|---|
| Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12 | -1.0 ± 0.34 | -1.4 ± 0.33 | -1.4 ± 0.33 | -1.0 ± 0.34 |
The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.
| score on a scale | Lanraplenib | Filgotinib | Tirabrutinib | Placebo |
|---|---|---|---|---|
| Change From Baseline in ESSDAI at Week 24 | -4.3 ± 0.81 | -5.4 ± 0.75 | -4.0 ± 0.75 | -4.2 ± 0.78 |
The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.
| score on a scale | Lanraplenib | Filgotinib | Tirabrutinib | Placebo |
|---|---|---|---|---|
| Change From Baseline in ESSPRI at Week 24 | -1.1 ± 0.34 | -0.8 ± 0.31 | -1.2 ± 0.31 | -0.9 ± 0.33 |
Collected over First dose date up to last dose date (Maximum: 50.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lanraplenib | 0/37 (0%) | 3/37 (8.1%) | 30/37 (81.1%) |
| Filgotinib | 0/38 (0%) | 5/38 (13.2%) | 31/38 (81.6%) |
| Tirabrutinib | 0/39 (0%) | 1/39 (2.6%) | 32/39 (82.1%) |
| Placebo to Lanraplenib | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Placebo to Filgotinib | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Placebo to Tirabrutinib | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Placebo on Placebo Controlled Period | 0/36 (0%) | 2/36 (5.6%) | 23/36 (63.9%) |
| Event | Lanraplenib | Filgotinib | Tirabrutinib | Placebo to Lanraplenib | Placebo to Filgotinib | Placebo to Tirabrutinib | Placebo on Placebo Controlled Period |
|---|---|---|---|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 0/38 | 0/39 | 0/10 | 1/12 | 0/10 | 0/36 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/37 | 0/38 | 0/39 | 0/10 | 0/12 | 0/10 | 1/36 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/37 | 0/38 | 0/39 | 0/10 | 0/12 | 0/10 | 1/36 |
| Acute coronary syndromeCardiac disorders | 1/37 | 0/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| Pancreatitis acuteGastrointestinal disorders | 1/37 | 0/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| Suicidal ideationPsychiatric disorders | 1/37 | 0/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| PancreatitisGastrointestinal disorders | 0/37 | 1/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| DiverticulitisInfections and infestations | 0/37 | 1/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| MigraineNervous system disorders | 0/37 | 1/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| Renal failureRenal and urinary disorders | 0/37 | 1/38 | 0/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| Event | Lanraplenib | Filgotinib | Tirabrutinib | Placebo to Lanraplenib | Placebo to Filgotinib | Placebo to Tirabrutinib | Placebo on Placebo Controlled Period |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/37 | 6/38 | 9/39 | 0/10 | 1/12 | 0/10 | 4/36 |
| FatigueGeneral disorders | 4/37 | 0/38 | 3/39 | 2/10 | 1/12 | 0/10 | 2/36 |
| Gastroenteritis viralInfections and infestations | 3/37 | 2/38 | 3/39 | 2/10 | 0/12 | 0/10 | 0/36 |
| NasopharyngitisInfections and infestations | 3/37 | 6/38 | 4/39 | 1/10 | 1/12 | 2/10 | 4/36 |
| Urinary tract infectionInfections and infestations | 1/37 | 2/38 | 4/39 | 2/10 | 2/12 | 0/10 | 6/36 |
| Neck painMusculoskeletal and connective tissue disorders | 0/37 | 1/38 | 1/39 | 2/10 | 0/12 | 0/10 | 0/36 |
| Temporomandibular joint syndromeMusculoskeletal and connective tissue disorders | 0/37 | 1/38 | 0/39 | 2/10 | 0/12 | 0/10 | 0/36 |
| DiarrhoeaGastrointestinal disorders | 3/37 | 3/38 | 3/39 | 1/10 | 2/12 | 0/10 | 1/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/37 | 4/38 | 6/39 | 0/10 | 0/12 | 0/10 | 0/36 |
| SinusitisInfections and infestations | 2/37 | 1/38 | 5/39 | 1/10 | 0/12 | 0/10 | 3/36 |
The Safety Analysis Set included participants who received at least one dose of study drug.
| Age, Continuous(years) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.2 ± 9.72 | 52.2 ± 10.54 | 55.8 ± 10.06 | 53.2 ± 10.28 | 54.4 ± 10.20 |
| Sex: Female, Male(Participants) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| Female | 36 | 38 | 37 | 35 | 146 |
| Male | 1 | 0 | 2 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 1 | 6 | 17 |
| Not Hispanic or Latino | 31 | 34 | 38 | 30 | 133 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 | 0 | 2 |
| Black | 5 | 5 | 4 | 5 | 19 |
| White | 31 | 32 | 34 | 30 | 127 |
| Other | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| United States | 26 | 27 | 30 | 23 | 106 |
| Poland | 7 | 4 | 5 | 6 | 22 |
| Spain | 2 | 4 | 3 | 4 | 13 |
| United Kingdom | 2 | 3 | 1 | 3 | 9 |
| European League Against Rheumatism (EULAR) Sjogren's syndrome disease activity index (ESSDAI)(Score on a scale) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 10.5 ± 4.89 | 10.2 ± 6.23 | 10.4 ± 5.36 | 9.3 ± 3.96 | 10.1 ± 5.16 |
| EULAR Sjogren's syndrome patient reported index (ESSPRI)(Score on a scale) | Lanraplenib | Filgotinib | Tirabrutinib | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 6.6 ± 1.90 | 6.3 ± 2.31 | 5.9 ± 2.39 | 5.9 ± 2.24 | 6.2 ± 2.22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Jan 2019, 20 months.
Results were first posted in Jan 2020, 1 year after primary completion.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lanraplenib · GLPG0634 · Tirabrutinib